Fewer than one in 10 patients who could benefit from GLP-1 drugs such as Wegovy are able to get them, caution the World Health Organization as it issues its initial recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging broader and more equitable access to these injectable treatments.
Per forecasts, over two billion could be obese by 2030 unless action is taken.
"Our latest guidelines recognises that excess weight is a chronic disease that can be addressed with holistic and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are significant obstacles to widespread availability to the treatments that can aid individuals in losing considerable body mass, notes the body.
Skinny Jab Scarcity
Even under the present best projected scenario, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The recommendation calls on governments and firms to expand access, through approaches such as patent sharing.
Exclusive production rights on a key compound – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Injections Function
The injections replicate a biological compound to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people reduce food intake.
People usually see weight reduction after several weeks of starting on the weekly injections.
Studies indicates users may regain a significant portion within a year of halting the treatment, as their usual appetite return.
Being above a healthy weight increases your chance for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight concerns individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.
